Corcept Therapeutics president trims holdings via 10b5-1 plan
Rhea-AI Filing Summary
Corcept Therapeutics (CORT) – Form 4 insider activity
Sean Maduck, President of Corcept Endocrinology, exercised low-priced options and immediately sold the underlying shares pursuant to a 10b5-1 plan:
- 17 Jul 2025: Exercised 4,315 options at $5.05; sold 4,315 shares at a weighted-avg $73.4771.
- 18 Jul 2025: Exercised 473 options at $5.05; sold 473 shares at $73.4404.
Total shares sold: 4,788; gross proceeds ≈ $351k; per-share spread ≈ $68.4.
Post-trade holdings: 17,705 shares direct; 99,693 shares indirect (89,693 trust + 10,000 LLC); 56,993 vested options; 1,877 unvested RSAs.
The divestiture equals ~4 % of Maduck’s reported equity exposure and was pre-scheduled, suggesting limited informational content for the broader CORT investment thesis.
Positive
- Officer retains ~117,000 shares and 56,993 options, preserving significant ownership alignment with shareholders
Negative
- Sale of 4,788 shares (~$351k) may be viewed as minor insider selling pressure despite 10b5-1 protection
Insights
TL;DR: Planned option exercise & sale by CORT officer; modest size, neutral market signal.
The transactions show an executive monetising ≈$351k via option exercises at $5.05 and same-day sales around $73.45. Because they were executed under a standing 10b5-1 plan, timing is not discretionary, reducing concern over negative insider sentiment. Maduck retains ~117k shares and nearly 57k additional options, maintaining strong alignment with shareholders. Scale of liquidation (~4 % of holdings) is not material to float or insider ownership metrics. I view the filing as routine housekeeping rather than a catalyst.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 473 | $0.00 | -- |
| Exercise | Common Stock | 473 | $5.05 | $2K |
| Sale | Common Stock | 473 | $73.4404 | $35K |
| Exercise | Stock option (right to buy) | 4,315 | $0.00 | -- |
| Exercise | Common Stock | 4,315 | $5.05 | $22K |
| Sale | Common Stock | 4,315 | $73.4771 | $317K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.47 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Fully exercisable.
